XML 58 R42.htm IDEA: XBRL DOCUMENT
v3.10.0.1

INTANGIBLE ASSETS, NET (Details Narrative) |  | 3 Months Ended | 12 Months Ended
--- | --- | --- | ---
Aug. 06, 2018 USD ($) $ / shares shares | Sep. 30, 2018 USD ($) | Dec. 31, 2018 USD ($) Number | Dec. 31, 2017 USD ($) | Dec. 31, 2016 USD ($)
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |
Amortization expense | $ |  |  | $ 112,474 | $ 71,516 | $ 54,545
Subscription Agreement [Member] | Knight Therapeutics Inc. [Member] |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |
Issue of common stock shares (in shares) | shares | 3,921,568 |  |  |  |
Common stock sale price (in dollars per share) | $ / shares | $ 5.10 |  |  |  |
Gross proceeds | $ | $ 20,000,000 |  |  |  |
Approved Hormone Therapy Drug Candidate Patents [Member] |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |
Useful Life |  |  | 20 years |  |
Domestic U.S. Patents [Member] |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |
Number of issued patents |  |  | 21 |  |
Foreign Patents [Member] |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |
Number of issued patents |  |  | 24 |  |
Domestic Utility Patents [Member] |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |
Number of issued patents |  |  | 11 |  |
Foreign Utility Patents [Member] |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |
Number of issued patents |  |  | 5 |  |
Domestic Patents - TX-004HR [Member] |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |
Number of issued patents |  |  | 3 |  |
Foreign Patents - TX-004HR [Member] |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |
Number of issued patents |  |  | 12 |  |
Domestic Utility Patent - Transdermal Patch Candidates [Member] |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |
Number of issued patents |  |  | 1 |  |
Foreign Utility Patent - Transdermal Patch Candidates [Member] |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |
Number of issued patents |  |  | 4 |  |
Domestic Utilty Patent - Opera Software [Member] |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |
Number of issued patents |  |  | 1 |  |
Domestic Patents - TX-009HR [Member] |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |
Number of issued patents |  |  | 1 |  |
Foreign Patents Progesterone - Only Candidate [Member] |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |
Number of issued patents |  |  | 3 |  |
Domestic Utility Patents Topical - Cream Candidates [Member] |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |
Number of issued patents |  |  | 1 |  |
Council License Agreement [Member] |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |
Payment of milestone recorded as finite-lived intangible asset | $ |  | $ 20,000,000 |  |  |
Council License Agreement [Member] | ANNOVERA [Member] |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |
Milestone payments upon FDA approval | $ |  |  | $ 20,000,000 |  |
Milestone payments (payment after release of first commercial batch) | $ |  |  | $ 20,000,000 |  |
Annual royalty rate reduction of initial rate during the six-month period from commercial sale of a generic equivalent |  |  | 50.00% |  |
Annual royalty rate reduction of initial rate after the six-month period from commercial sale of a generic equivalent |  |  | 20.00% |  |
Maximum costs and expenses for post approval study to be paid by the Company | $ |  |  | $ 20,000,000 |  |
Council License Agreement [Member] | ANNOVERA [Member] | Step-based Royalty Payment One [Member] |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |
Royalty (percent) |  |  | 5.00% |  |
Council License Agreement [Member] | ANNOVERA [Member] | Step-based Royalty Payment One [Member] | Maximum [Member] |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |
Net sales amount per step-based royalty | $ |  |  | $ 50,000,000 |  |
Council License Agreement [Member] | ANNOVERA [Member] | Step-based Royalty Payment Three [Member] |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |
Royalty (percent) |  |  | 15.00% |  |
Council License Agreement [Member] | ANNOVERA [Member] | Step-based Royalty Payment Three [Member] | Minimum [Member] |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |
Net sales amount per step-based royalty | $ |  |  | $ 150,000,000 |  |
Council License Agreement [Member] | ANNOVERA [Member] | Step-based Royalty Payment Two [Member] |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |
Royalty (percent) |  |  | 10.00% |  |
Council License Agreement [Member] | ANNOVERA [Member] | Step-based Royalty Payment Two [Member] | Minimum [Member] |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |
Net sales amount per step-based royalty | $ |  |  | $ 50,000,000 |  |
Council License Agreement [Member] | ANNOVERA [Member] | Step-based Royalty Payment Two [Member] | Maximum [Member] |  |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |  |
Net sales amount per step-based royalty | $ |  |  | $ 150,000,000 |  |

X
- Definition The reduction in royalty rate of initial rate six-months after the first arms-length commercial sale of a generic equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S. + References No definition available. + Details
Name: | txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent
Namespace Prefix: | txmd_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The reduction in royalty rate of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S. + References No definition available. + Details
Name: | txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent
Namespace Prefix: | txmd_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The maximum amount of costs and expenses associated with a post approval study required by the FDA to measure risk for venous thromboembolism to be paid by the Company before any such excess will be offset against royalties or other payments owed by us to the Population Council under the Council License Agreement. + References No definition available. + Details
Name: | txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of milestone payments payable after release of first commercial batch. + References No definition available. + Details
Name: | txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of milestone payments payable upon FDA approval. + References No definition available. + Details
Name: | txmd_MilestonePaymentsUponFDAApproval
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The net sales amount as defined in license agreement for step-based royalty payments. + References No definition available. + Details
Name: | txmd_NetSalesAmountPerStepbasedRoyalty
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of issued patents. + References No definition available. + Details
Name: | txmd_NumberOfIssuedPatents
Namespace Prefix: | txmd_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition The cash inflow from the additional capital contribution to the entity. + References No definition available. + Details
Name: | txmd_ProceedsFromIssuanceOfCommonStock1
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The percent of the net sales to be paid as royalty per license agreement. + References No definition available. + Details
Name: | txmd_RoyaltyPercent
Namespace Prefix: | txmd_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274 + Details
Name: | us-gaap_AmortizationOfIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275 + Details
Name: | us-gaap_FinitelivedIntangibleAssetsAcquired1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + References No definition available. + Details
Name: | us-gaap_SaleOfStockPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of new stock issued during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=txmd_SubscriptionAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=txmd_KnightTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents5Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents3Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents1Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents6Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents4Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents7Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents2Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents8Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents9Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents10Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents11Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreement1Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=txmd_AnnoveraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | txmd_RoyaltyTierAxis=txmd_StepBasedRoyaltyPaymentOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | txmd_RoyaltyTierAxis=txmd_StepBasedRoyaltyPaymentThreeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | txmd_RoyaltyTierAxis=txmd_StepBasedRoyaltyPaymentTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |